GlassScriptPhysician profile
Amy M Archer
NPI 1497972251
$1,173.69
in general payments reported to CMS, 2019-2025
22 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.12 · 2020: $110 · 2022: $183 · 2023: $304 · 2024: $372 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $783.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $783.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $269.47 | 2020-2025 | Otezla, Evenity, Repatha |
| Abbvie INC. | $267.78 | 2022-2025 | Qulipta, Ubrelvy, Linzess |
| Novo Nordisk INC | $148.54 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $61.61 | 2023-2024 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $55.28 | 2022-2023 | Shingrix, Arexvy |
| Pfizer INC. | $46.43 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.47 | 2023-2024 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.42 | 2024 | Xifaxan, Trulance |
| Ironshore Pharmaceuticals INC. | $33.48 | 2020-2022 | |
| Allergan, INC. | $24.39 | 2019 | |
| Sunovion Pharmaceuticals INC. | $22.39 | 2020 | |
| Bard Peripheral Vascular, INC. | $20.24 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.84 | 2024 | Trintellix |
| Nevro Corp. | $17.24 | 2023 | Senza |
| Merck Sharp & Dohme LLC | $15.82 | 2024 | Capvaxive, Gardasil 9, Vaxelis |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $15.45 | 2022 | |
| Amneal Pharmaceuticals LLC | $15.19 | 2023 | Unithroid |
| Idorsia Pharmaceuticals US INC | $14.58 | 2024 | Quviviq |
| Alkermes, INC. | $14.29 | 2023 | Lybalvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.09 | 2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $13.14 | 2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $12.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Archer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.